New hope could be on the horizon for ALS patients in the form of a "breakthrough" drug, researchers say. Neuvivo, a California biopharmaceutical company that develops therapies for neurodegenerative ...

Acurastem has received $7.5 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance AS-241, its lead clinical candidate for amyotrophic lateral sclerosis (ALS) and ...

Researchers at the Johns Hopkins University School of Medicine and the National Institutes of Health, in collaboration with the UK Biobank and the University of Turin, Italy, have identified a ...

GENEVA--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and ...

Researchers have developed a gene therapy that significantly slowed motor function loss in preclinical models of amyotrophic lateral sclerosis (ALS), offering new hope for treating the devastating ...

Together with the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, the Les Turner ALS Center at Northwestern Medicine is thrilled to announce the launch of the Acceleration ...

The UAB ALS Multidisciplinary Clinic has been designated a Certified Treatment Center of Excellence (CTCE) by the ALS Association, a recognition that underscores its commitment to providing the ...

Patients with ALS, or Lou Gehrig's disease, live an average of only three years after symptoms begin, though some can survive ...

Evidence is emerging that amyotrophic lateral sclerosis (ALS) may have an autoimmune component — a finding that, if confirmed, could shape the development of new therapies and prognostic tools.

ALS is characterized by the death of motor neurons, leading to progressive muscle weakness and loss of voluntary movement. Sporadic ALS accounts for approximately 90-95% of cases, while familial ALS ...

Paul Francoeur's voice cloned using 14-year-old WCAX story ...